HER2 mutations mainly occur at exon 20 in the protein kinase domain and are recognized as primary drivers in lung cancer, similar to other oncogenic drivers, such as EGFR, ROS, ALK, KRAS and BRAF (11). This evidence concerns the gene ALK and lung carcinoma.